申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0203721A2
公开(公告)日:1986-12-03
The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine.
本发明涉及某些新型 8-苯基黄嘌呤,其苯基的 3 或 4 位被带有末端酸性基团的烯基、烯氧基、炔基或炔氧基取代,并涉及它们在人类和兽医治疗中的用途,特别是用于治疗与腺苷的细胞表面效应有关的疾病。